Cited 17 times in
Chemotherapy-induced irreversible alopecia in early breast cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2018-07-20T07:29:05Z | - |
dc.date.available | 2018-07-20T07:29:05Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160210 | - |
dc.description.abstract | PURPOSE: The purpose of this work is to determine the prevalence of chemotherapy-induced irreversible alopecia (CIIA), which is defined as an alopecia that exists at least 6 months after completion of chemotherapy and factors affecting CIIA in early breast cancer patients. METHODS: We performed a cross-sectional study. We retrospectively identified breast cancer patients who had received AC (Adriamycin, Cyclophosphamide) or AC-T (AC followed by Taxane) as neoadjuvant or adjuvant chemotherapy. We conducted questionnaire survey regarding alopecia and measured hair density using phototrichogram. RESULTS: From February 2015 to May 2015, among 265 patients who responded properly to the questionnaire, the women who answered they had severe alopecia (alopecia > 50% of scalp) were 19 patients (7.2%). AC-only and AC-T treated patients reported severe alopecia in 2.7% and 10.5%, respectively, which were significantly different (p < 0.001). Mean hair density was 75 hair/cm2 (range 42-112) and 75.2/cm2 (range 48.3-102) on occipital area and vertex area, respectively. Hair loss was the most frequent in parietal area (42.6%). Half of total patients (46%) and 73% of CIIA patients regarded that their hair became thinner after chemotherapy CONCLUSIONS: We found that significant proportion of early breast cancer patients were suffering from severe CIIA, especially when they had been treated with AC followed by taxane regimen. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Kluwer Academic | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Alopecia/chemically induced | - |
dc.subject.MESH | Alopecia/epidemiology | - |
dc.subject.MESH | Alopecia/pathology* | - |
dc.subject.MESH | Breast Neoplasms/complications* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy | - |
dc.subject.MESH | Breast Neoplasms/epidemiology | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Bridged-Ring Compounds/administration & dosage | - |
dc.subject.MESH | Bridged-Ring Compounds/adverse effects | - |
dc.subject.MESH | Chemotherapy, Adjuvant/adverse effects* | - |
dc.subject.MESH | Cross-Sectional Studies | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Cyclophosphamide/adverse effects | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Doxorubicin/adverse effects | - |
dc.subject.MESH | Drug-Related Side Effects and Adverse Reactions/pathology* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Taxoids/adverse effects | - |
dc.title | Chemotherapy-induced irreversible alopecia in early breast cancer patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Sanghwa Kim | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.contributor.googleauthor | Jee Ye Kim | - |
dc.contributor.googleauthor | Sanggen Nam | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | DoYoung Kim | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.identifier.doi | 10.1007/s10549-017-4204-x | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A00384 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 28324267 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs10549-017-4204-x | - |
dc.subject.keyword | Adverse reactions | - |
dc.subject.keyword | Alopecia | - |
dc.subject.keyword | Antineoplastic agents | - |
dc.subject.keyword | Breast neopla는 | - |
dc.subject.keyword | Drug-related side effects | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Park, Hyung Seok | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Park, Hyung Seok | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.citation.volume | 163 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 527 | - |
dc.citation.endPage | 533 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, Vol.163(3) : 527-533, 2017 | - |
dc.identifier.rimsid | 39066 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.